Reversion of hormone treatment resistance with the addition of an mtor inhibitor in endometrial stromal sarcoma

Case Reports in Medicine

Volumn 2014, Issue , 2014, Pages

  Martin Liberal, J ^a   Benson, C ^a   Messiou, C ^a   Fisher, C ^a   Judson, I ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; RAPAMYCIN;

ABDOMINAL DISCOMFORT; ABDOMINAL HYSTERECTOMY; ABDOMINAL PAIN; ADULT; ARTICLE; CANCER HORMONE THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; ENDOMETRIUM SARCOMA; FEMALE; HISTOPATHOLOGY; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; MIDDLE AGED; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVARIECTOMY; PERITONEUM TUMOR; QUALITY OF LIFE; REPEAT PROCEDURE; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84940519336     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2014/612496     Document Type: Article

References (37)

1. Ferrari A., Sultan I., Huang T. T., Rodriguez-Galindo C., Shehadeh A., Meazza C., Ness K. K., Casanova M., Spunt S. L., Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatric Blood and Cancer 2011 57 6 943 949 10.1002/pbc.23252 2-s2.0-80052664254
2. Thanopoulou E., Judson I., Hormonal therapy in gynecological sarcomas. Expert Review of Anticancer Therapy 2012 12 7 885 894 10.1586/era.12.74 2-s2.0-84864612970
3. D'Angelo E., Prat J., Uterine sarcomas: a review. Gynecologic Oncology 2010 116 1 131 139 10.1016/j.ygyno.2009.09.023 2-s2.0-70749135317
4. Koivisto-Korander R., Butzow R., Koivisto A., Leminen A., Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumor Biology 2011 32 3 451 459 10.1007/s13277-010-0138-1 2-s2.0-79960593150
5. Chu M. C., Mor G., Lim C., Zheng W., Parkash V., Schwartz P. E., Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecologic Oncology 2003 90 1 170 176 10.1016/S0090-8258(03)00258-0 2-s2.0-0037824470 (Pubitemid 37338093)
6. Cheng X., Yang G., Schmeler K. M., Coleman R. L., Tu X., Liu J., Kavanagh J. J., Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecologic Oncology 2011 121 2 323 327 10.1016/j.ygyno.2010.12.360 2-s2.0-79955481960
7. Pink D., Lindner T., Mrozek A., Kretzschmar A., Thuss-Patience P. C., Dörken B., Reichardt P., Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature. Gynecologic Oncology 2006 101 3 464 469 10.1016/j.ygyno.2005.11.010 2-s2.0-33745324082 (Pubitemid 44251067)
8. Akhan S. E., Yavuz E., Tecer A., Iyibozkurt C. A., Topuz S., Tuzlali S., Bengisu E., Berkman S., The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecologic Oncology 2005 99 1 36 42 10.1016/j.ygyno.2005.05.019 2-s2.0-25144474865 (Pubitemid 41354580)
9. Ioffe Y. J., Li A. J., Walsh C. S., Karlan B. Y., Leuchter R., Forscher C., Cass I., Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecologic Oncology 2009 115 3 466 471 10.1016/j.ygyno.2009. 08.014 2-s2.0-70350567746
10. Spano J., Soria J.-C., Kambouchner M., Piperno-Neuman S., Morin F., Morere J., Martin A., Breau J., Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Medical Oncology 2003 20 1 87 93 10.1385/MO:20:1:87 2-s2.0-0348047571 (Pubitemid 36344030)
11. Dahhan T., Fons G., Buist M. R., ten Kate F. J. W., van der Velden J., The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. European Journal of Obstetrics & Gynecology and Reproductive Biology 2009 144 1 80 84 10.1016/j.ejogrb.2009.02.005 2-s2.0-64149094349
12. Leunen M., Breugelmans M., de Sutter P., Bourgain C., Amy J. J., Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecologic Oncology 2004 95 3 769 771 10.1016/j.ygyno.2004.07.063 2-s2.0-9944265404 (Pubitemid 39592558)
13. Shoji K., Oda K., Nakagawa S., Kawana K., Yasugi T., Ikeda Y., Takazawa Y., Kozuma S., Taketani Y., Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. Medical Oncology 2011 28 3 771 774 10.1007/s12032-010-9511-6 2-s2.0-80052503481
14. Reich O., Regauer S., Hormonal therapy of endometrial stromal sarcoma. Current Opinion in Oncology 2007 19 4 347 352 10.1097/CCO.0b013e3281a7ef3a 2-s2.0-34250016061 (Pubitemid 46883524)
15. Amant F., Coosemans A., Debiec-Rychter M., Timmerman D., Vergote I., Clinical management of uterine sarcomas. The Lancet Oncology 2009 10 12 1188 1198 10.1016/S1470-2045(09)70226-8 2-s2.0-70649089394
16. Brown K. A., Samarajeewa N. U., Simpson E. R., Endocrine-related cancers and the role of AMPK. Molecular and Cellular Endocrinology 2013 366 2 170 179 10.1016/j.mce.2012.06.016 2-s2.0-84872649836
17. Attard G., Richards J., de Bono J. S., New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clinical Cancer Research 2011 17 7 1649 1657 10.1158/1078-0432.CCR-10-0567 2-s2.0-79953320228
18. Smith I. E., Dowsett M., Aromatase inhibitors in breast cancer. The New England Journal of Medicine 2003 348 24 2431 2442 10.1056/NEJMra023246 2-s2.0-0038210242 (Pubitemid 36682823)
19. Nabholtz J. M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., Von Euler M., Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Journal of Clinical Oncology 2000 18 22 3758 3767 2-s2.0-0034669484
20. Bonneterre J., Thürlimann B., Robertson J. F. R., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., Von Euler M., Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. Journal of Clinical Oncology 2000 18 22 3748 3757 2-s2.0-0034669435
21. Mouridsen H., Gershanovich M., Sun Y., Pérez-Carrión R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H. P., Jänicke F., Pluzanska A., Dank M., Becquart D., Bapsy P. P., Salminen E., Snyder R., Lassus M., Verbeek J. A., Staffler B., Chaudri-Ross H. A., Dugan M., Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. Journal of Clinical Oncology 2001 19 10 2596 2606 2-s2.0-0343584508 (Pubitemid 32451796)
22. Mauri D., Pavlidis N., Polyzos N. P., Ioannidis J. P. A., Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Journal of the National Cancer Institute 2006 98 18 1285 1291 10.1093/jnci/djj357 2-s2.0-33749003747 (Pubitemid 44530724)
23. Schiff R., Massarweh S. A., Shou J., Bharwani L., Mohsin S. K., Osborne C. K., Nicholson R., Ellis M., Santen R., Brown M., Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 2004 10 1, part 2 331S 336S 10.1158/1078-0432.CCR-031212 2-s2.0-9144256614 (Pubitemid 38116639)
24. Johnston S. R. D., Arteaga C., Winer E., Dowsett M., Kumar R., Come S., Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clinical Cancer Research 2006 12 3, part 2 1061s 1068s 10.1158/1078-0432.CCR-05-2125 2-s2.0-32944466881 (Pubitemid 43259844)
25. Burstein H. J., Novel agents and future directions for refractory breast cancer. Seminars in Oncology 2011 38 supplement 2 S17 S24 10.1053/j.seminoncol. 2011.04.002 2-s2.0-79956195555
26. Baselga J., Campone M., Piccart M., Burris H. A. III, Rugo H. S., Sahmoud T., Noguchi S., Gnant M., Pritchard K. I., Lebrun F., Beck J. T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G. N., Everolimus in postmenopausal hormone-receptor- positive advanced breast cancer. The New England Journal of Medicine 2012 366 6 520 529 10.1056/NEJMoa1109653 2-s2.0-84863078767
27. Thomas C., Lamoureux F., Crafter C., Davies B. R., Beraldi E., Fazli L., Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Molecular Cancer Therapeutics 2013 12 11 2342 2355
28. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009 45 2 228 247 10.1016/j.ejca.2008.10.026 2-s2.0-57849117384
29. Choi H., Charnsangavej C., Faria S. C., Macapinlac H. A., Burgess M. A., Patel S. R., Chen L. L., Podoloff D. A., Benjamin R. S., Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Journal of Clinical Oncology 2007 25 13 1753 1759 10.1200/JCO.2006.07.3049 2-s2.0-34249085905 (Pubitemid 46797957)
30. Reichardt P., The treatment of uterine sarcomas. Annals of Oncology 2012 23 supplement 10 x151 x157 10.1093/annonc/mds359 2-s2.0-84866753945
31. Chan J. K., Kawar N. M., Shin J. Y., Osann K., Chen L.-., Powell C. B., Kapp D. S., Endometrial stromal sarcoma: a population-based analysis. The British Journal of Cancer 2008 99 8 1210 1215 10.1038/sj.bjc.6604527 2-s2.0-53849101802
32. Seddon B. M., Davda R., Uterine sarcomas-recent progress and future challenges. European Journal of Radiology 2011 78 1 30 40 10.1016/j.ejrad.2010. 12.057 2-s2.0-79954706262
33. Yamnik R. L., Holz M. K., mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation. FEBS Letters 2010 584 1 124 128 10.1016/j.febslet.2009.11.041 2-s2.0-71549166007
34. Yamnik R. L., Digilova A., Davis D. C., Brodt Z. N., Murphy C. J., Holz M. K., S6 kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation. Journal of Biological Chemistry 2009 284 10 6361 6369 10.1074/jbc.M807532200 2-s2.0-65249190250
35. Demetri G. D., Chawla S. P., Ray-Coquard I., le Cesne A., Staddon A. P., Milhem M. M., Penel N., Riedel R. F., Bui-Nguyen B., Cranmer L. D., Reichardt P., Bompas E., Alcindor T., Rushing D., Song Y., Lee R., Ebbinghaus S., Eid J. E., Loewy J. W., Haluska F. G., Dodion P. F., Blay J., Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. Journal of Clinical Oncology 2013 31 19 2485 2492 10.1200/JCO.2012.45.5766 2-s2.0-84883063380
36. Chawla S. P., Staddon A. P., Baker L. H., Schuetze S. M., Tolcher A. W., D'Amato G. Z., Blay J., Mita M. M., Sankhala K. K., Berk L., Rivera V. M., Clackson T., Loewy J. W., Haluska F. G., Demetri G. D., Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. Journal of Clinical Oncology 2012 30 1 78 84 10.1200/JCO.2011.35.6329 2-s2.0-84855556875
37. Tirumani S. H., Jagannathan J. P., O'Regan K., Kim K. W., Krajewski K. M., Ramaiya N. H., Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know. Cancer Imaging 2013 13 2 197 211 10.1102/1470-7330.2013.0022 2-s2.0-84877857176